___

• Dekel A, Efrat Z, Orvieto R, Levy T, Dicker D, Gal R.et al. The residual ovary syndrome: a 20-year experience. Eur Biol 1996; 68:159–64. Gynecol Reprod
• Fong YF, Lim FK, Arulkumaran S. Prophylactic oophorectomy: a continuing controversy. Obstet Gynecol Surv 1998; 53:493–99.
• Reich H. Issues surrounding surgical menopause. J Reprod Med 2001;46:297–306.
• Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo study. J Clin Endocrinol Metab 2000;85:645–51. p* AMH ( ng/ml) Histerektomi öncesi
• Histerektomi sonrası Sağ Over Hacmi (ml) Histerektomi öncesi Histerektomi sonrası 28 0,71 ± 0,87 0,45 ± 0,62 0,345 (0,03 - 3,56) 0,0001 28 0,090 (0,04 - 2,65) 28 7,26 ± 3,90 7,58 ± 5,86 6,20 (1,90 – 18,40) 5,79 (2,20 – 30,50) 0,048 28 Sol Over Hacmi (ml) Histerektomi öncesi
• Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005;16:556–62.
• Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105–10.
• Falkeborn M, Schairer C, Naessén T, Persson I. Risk of myocardial infarction after oophorectomy and hysterectomy. J Clin Epidemiol 2000;53:832–7.
• Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265–79. Armstrong K, Schwartz JS, Randall T, Rubin
• SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045–54.
• Lambalk CB. Value of elevated basal follicle- stimulating hormone levels and the differential diagnosis during the diagnostic subfertility work-up. Fertil Steril 2003;79:489-90.
• Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy Ch, Englert Y.et al. Stable serum levels of anti- Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 2007;22:1837-40.
• Van Rooij IA, Tonkelaar Id, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, et al. Anti-Mülleryan hormone is a promising predictor for the occurrence of 2004;11:601–6. transition. Menopause
• Atabekoglu C, Taskin S, Kahraman K, Gemici A, Taskin EA, Ozmen B,et al. The effect of total abdominal hysterectomy on serum anti-Mullerian hormone study. Climacteric. 2012;15:393–7. levels:a pilot
• YuanH, WangC, WangD, WangY.Comparison ofthe effect of laparoscopic supracervical hysterectomy for uterine fibroids on ovarian reserve by assessing serum anti-Mullerian hormone levels: a prospective cohort study. J Minim Invasive Gynecol. 2015:22:637-41. and total
• Moorman PG, Myers ER, Schildkraut JM, Iversen ES, Wang F, Warren N. Effect of Hysterectomy With Ovarian Preservation on Ovarian Function. Obstet Gynecol 2011;118: 1271–9
• Wang HY, Quan S, Zhang RL, Ye HY, Bi YL, Jiang ZM, Ng EH. Comparison of serum anti-Mullerian hormone myomectomy conditions. Eur Biol. 2013;171:368-71 hysterectomy and for J Obstet Gynecol Reprod
• Cattanach J. Oestrogen deficiency after tubal ligation. Lancet 1985;1:847-9.
• Janson PO, Jansson I. The acute effect of hysterectomyon ovarian blood flow. Am J Obstet Gynecol 1977;127:349-52
• Chrisman HB, Saker MB, Ryu RK, Nemcek AA Jr, Gerbie MV, Milad MP. et al. The impact of uterine fibroid embolization on resumption of menses and ovarian function. J Vasc Interv Radial 2000;11:699-703